US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

132.47

-0.2600-0.20%

Post-market: 132.01-0.4600-0.35%19:59 EDT

Volume:348.11K

Turnover:45.69M

Market Cap:1.91B

PE:-27.05

High:137.04

Open:135.15

Low:127.26

Close:132.73

52wk High:161.38

52wk Low:61.73

Shares:14.41M

Float Shares:8.40M

Volume Ratio:1.45

T/O Rate:4.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.8978

EPS(LYR):-3.7076

ROE:-46.63%

ROA:-22.05%

PB:8.80

PE(LYR):-35.73

Loading ...

Overview Company News Filings

Palvella receives third year of grant funding from FDA for QTORIN

FDA Awards Palvella Third-Year Orphan Grant Funding for Qtorin Rapamycin Phase 3 SELVA Trial

U.S. Food and Drug Administration Awards Additional Funding for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

THOMSON REUTERS

Palvella Therapeutics COO Kathleen Goin Disposes of 4,302 Common Shares Worth $656,426.82

Palvella Therapeutics Director George M. Jenkins Disposes of USD 4.15 Million in Common Shares

Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Palvella Therapeutics Names Pediatric Dermatologist James Treat Chief Medical Officer

Palvella Therapeutics Appoints James R. Treat, M.d., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer

THOMSON REUTERS

Palvella Therapeutics Director Makes Eye-Catching Insider Move in Latest Stock Transaction

Palvella Therapeutics Director Christopher P. Kiritsy Disposes of 313 Common Shares for $49,141

Palvella Therapeutics CEO to Speak at Cantor Global Healthcare Conference 2026

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

Palvella Completes Rolling FDA NDA Submission for Qtorin Rapamycin in Microcystic Lymphatic Malformations

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

THOMSON REUTERS

Palvella Therapeutics - Accelerating U.S. Launch Readiness for Potential Qtorin Rapamycin Launch in H1 2027 if Approved

THOMSON REUTERS

Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Palvella Therapeutics Charts Clear Path From Data To Launch

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/PVLA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":132.47,"timestamp":1790971200000,"preClose":132.73,"halted":0,"volume":348110,"hourTrading":{"tag":"盘后","latestPrice":132.01,"preClose":132.47,"latestTime":"19:59 EDT","volume":14126,"amount":1873246.14,"timestamp":1790985552242,"change":-0.46,"changeRate":-0.003472,"amplitude":0.028157},"delay":0,"changeRate":-0.0019588638589617337,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"Market Closed","change":-0.26,"latestTime":"10-02 16:00:00 EDT","open":135.15,"high":137.0364,"low":127.26,"amount":45686426.348500006,"amplitude":0.073656,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":132.73,"preHourTrading":{"tag":"盘前","latestPrice":133.4,"preClose":132.73,"latestTime":"09:16 EDT","volume":68,"amount":9066.48964,"timestamp":1790946999225,"change":0.67,"changeRate":0.005048,"amplitude":0.005651},"postHourTrading":{"tag":"盘后","latestPrice":132.01,"preClose":132.47,"latestTime":"19:59 EDT","volume":14126,"amount":1873246.14,"timestamp":1790985552242,"change":-0.46,"changeRate":-0.003472,"amplitude":0.028157},"volumeRatio":1.4473365840483827,"impliedVol":0.4645,"impliedVolPercentile":0.0438},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":8398100,"roa":"-22.05%","roe":"-46.63%","lyrEps":-3.707588,"volumeRatio":1.4473365840483827,"shares":14408407,"dividePrice":0,"high":137.0364,"amplitude":0.073656,"preClose":132.73,"low":127.26,"week52Low":61.728,"pbRate":"8.80","week52High":161.38,"institutionHeld":0,"latestPrice":132.47,"eps":-4.897784,"divideRate":0,"volume":348110,"delay":0,"ttmEps":-4.897784,"open":135.15,"prevYearClose":104.67,"prevWeekClose":138.16,"prevMonthClose":137.93,"prevQuarterClose":137.93,"fiveDayClose":138.16,"twentyDayClose":155.47,"sixtyDayClose":151.04},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"PVLA","fiscalQuarterEnding":"2026/06","expectedEps":-1.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-1.52},{"market":"US","date":"2026-05-07","symbol":"PVLA","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.2},{"market":"US","date":"2026-03-31","symbol":"PVLA","fiscalQuarterEnding":"2025/12","expectedEps":-0.95,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-1.08},{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1778558400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-10-02","current":-27.046926,"percent":0.426339,"low":-60.48704,"twenty":-36.575615,"median":-28.915921,"eighty":-11.316694,"high":46.119317,"avg":-20.551118,"sd":23.962475,"marketCap":1912427861},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-20","current":-29.573265,"twenty":-29.488024,"median":-17.242297,"eighty":19.914003,"marketCap":974498221},{"date":"2026-02-27","current":-60.48704,"twenty":-29.707799,"median":-17.512905,"eighty":19.303319,"marketCap":1993168926},{"date":"2026-03-06","current":-55.02714,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"marketCap":1813254325},{"date":"2026-03-13","current":-55.699943,"twenty":-30.574428,"median":-17.963839,"eighty":19.083855,"marketCap":1835424534},{"date":"2026-03-20","current":-46.447881,"twenty":-31.137829,"median":-18.431476,"eighty":19.083855,"marketCap":1530550575},{"date":"2026-03-27","current":-47.956591,"twenty":-32.06614,"median":-18.561811,"eighty":19.083855,"marketCap":1580265588},{"date":"2026-04-02","current":-41.305964,"twenty":-32.945472,"median":-18.707892,"eighty":19.083855,"marketCap":1723078270},{"date":"2026-04-10","current":-44.675498,"twenty":-33.393759,"median":-19.095844,"eighty":19.083855,"marketCap":1863638401},{"date":"2026-04-17","current":-42.609857,"twenty":-34.004406,"median":-19.561706,"eighty":18.969352,"marketCap":1777470174},{"date":"2026-04-24","current":-43.594639,"twenty":-34.788907,"median":-19.977117,"eighty":18.816681,"marketCap":1818550375},{"date":"2026-05-01","current":-44.030414,"twenty":-35.208457,"median":-20.266831,"eighty":18.756249,"marketCap":1836728722},{"date":"2026-05-08","current":-32.885673,"twenty":-35.663927,"median":-20.816267,"eighty":1.605963,"marketCap":1621165018},{"date":"2026-05-15","current":-34.614036,"twenty":-35.663927,"median":-21.021819,"eighty":-9.854931,"marketCap":1706368150},{"date":"2026-05-22","current":-33.726646,"twenty":-35.536117,"median":-21.24101,"eighty":-10.054175,"marketCap":1662622476},{"date":"2026-05-29","current":-33.709189,"twenty":-35.477208,"median":-21.439742,"eighty":-10.192113,"marketCap":1661761905},{"date":"2026-06-05","current":-33.406604,"twenty":-35.361812,"median":-22.020353,"eighty":-10.267821,"marketCap":1646845348},{"date":"2026-06-12","current":-30.951006,"twenty":-35.258528,"median":-22.098288,"eighty":-10.422477,"marketCap":1525791744},{"date":"2026-06-18","current":-32.769429,"twenty":-35.21133,"median":-22.480166,"eighty":-10.551201,"marketCap":1615434519},{"date":"2026-06-26","current":-39.627064,"twenty":-35.273781,"median":-22.826974,"eighty":-10.561865,"marketCap":1953495352},{"date":"2026-07-02","current":-40.226416,"twenty":-35.557603,"median":-22.973101,"eighty":-10.565696,"marketCap":1983041611},{"date":"2026-07-10","current":-43.944726,"twenty":-36.020976,"median":-23.275097,"eighty":-10.575275,"marketCap":2166343157},{"date":"2026-07-17","current":-42.993327,"twenty":-36.290379,"median":-24.416835,"eighty":-10.577479,"marketCap":2119442057},{"date":"2026-07-24","current":-41.665152,"twenty":-36.922579,"median":-25.632611,"eighty":-10.577479,"marketCap":2053966975},{"date":"2026-07-31","current":-43.697421,"twenty":-37.223591,"median":-27.238059,"eighty":-10.749704,"marketCap":2154151740},{"date":"2026-08-07","current":-36.182159,"twenty":-37.223591,"median":-27.449273,"eighty":-10.795027,"marketCap":2232294496},{"date":"2026-08-14","current":-36.560492,"twenty":-37.14313,"median":-27.55759,"eighty":-10.795594,"marketCap":2255636115},{"date":"2026-08-21","current":-33.297956,"twenty":-36.964247,"median":-27.969419,"eighty":-10.845405,"marketCap":2054350670},{"date":"2026-08-28","current":-35.107881,"twenty":-36.922579,"median":-28.427404,"eighty":-10.961312,"marketCap":2166015824},{"date":"2026-09-04","current":-36.30827,"twenty":-36.860843,"median":-28.502544,"eighty":-11.000041,"marketCap":2240075036},{"date":"2026-09-11","current":-35.121893,"twenty":-36.771144,"median":-28.581687,"eighty":-11.069277,"marketCap":2166880328},{"date":"2026-09-18","current":-36.039701,"twenty":-36.647633,"median":-28.648671,"eighty":-11.175559,"marketCap":2223505368},{"date":"2026-09-25","current":-34.113006,"twenty":-36.647633,"median":-28.73632,"eighty":-11.237188,"marketCap":2104636010},{"date":"2026-10-02","current":-30.997599,"twenty":-36.575615,"median":-28.915921,"eighty":-11.316694,"marketCap":1912427861}],"updateTime":1791064892260},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670234701","title":"Palvella receives third year of grant funding from FDA for QTORIN","url":"https://stock-news.laohu8.com/highlight/detail?id=2670234701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670234701?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:50","pubTimestamp":1790596216,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced that the Company has received a third year of grant funding from the FDA Office of Orphan Products Developme...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-receives-third-year-of-grant-funding-from-fda-for-qtorin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-receives-third-year-of-grant-funding-from-fda-for-qtorin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4585","LABU","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670423109","title":"FDA Awards Palvella Third-Year Orphan Grant Funding for Qtorin Rapamycin Phase 3 SELVA Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2670423109","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670423109?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:30","pubTimestamp":1790595023,"startTime":"0","endTime":"0","summary":"FDA awards Palvella third-year orphan grant funding for QTORIN rapamycin Phase 3 SELVA trialPalvella Therapeutics received a third year of FDA Orphan Products Development grant funding for its Phase 3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDLbNLRMJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","LU2095319765.USD","SG9999014021.USD","BK4588","BK4585","IE00B3QW5Z07.USD","BCDF","IE00BN0W2V16.EUR","NDAQ","PVLA","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","IE00BQXX3F31.USD","SG9999014005.SGD","BK4139","SG9999014039.USD","BK4112","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670310382","title":"U.S. Food and Drug Administration Awards Additional Funding for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2670310382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670310382?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:30","pubTimestamp":1790595017,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45K0E7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668978038","title":"Palvella Therapeutics COO Kathleen Goin Disposes of 4,302 Common Shares Worth $656,426.82","url":"https://stock-news.laohu8.com/highlight/detail?id=2668978038","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668978038?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:05","pubTimestamp":1789761951,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics COO Kathleen Goin disposes of 4,302 common shares worth $656,426.82Palvella Therapeutics COO Kathleen Goin exercised stock options for 4,302 common shares on Sep. 16, 2026.Option","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL8TSKrJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Palvella Therapeutics COO Kathleen Goin Disposes of 4,302 Common Shares Worth $656,426.82","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667675633","title":"Palvella Therapeutics Director George M. Jenkins Disposes of USD 4.15 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2667675633","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667675633?lang=en_us&edition=fundamental","pubTime":"2026-09-16 09:15","pubTimestamp":1789521359,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics director George M. Jenkins disposes of USD 4.15 million in common sharesPalvella Therapeutics director George M. Jenkins sold 27,500 common shares on Sep. 11-15.Sales priced betw","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL5T4hTy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Palvella Therapeutics Director George M. Jenkins Disposes of USD 4.15 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666594181","title":"Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666594181","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666594181?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:55","pubTimestamp":1789052115,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Palvella Therapeutics today and set a price target of $240.00. Suvannavejh c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666058059","title":"Palvella Therapeutics Names Pediatric Dermatologist James Treat Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666058059","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666058059?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:32","pubTimestamp":1788953570,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics names pediatric dermatologist James Treat chief medical officerPalvella Therapeutics appointed James R. Treat as chief medical officer, effective Dec. 21, 2026.Treat most recentl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL5Rk3kQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","SG9999014005.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","BCDF","SG9999014013.SGD","LU2210149790.SGD","BK4112","PVLA","IE00BN0W2T93.GBP","BK4139","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4588","IE00B3QW5Z07.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458037","title":"Palvella Therapeutics Appoints James R. Treat, M.d., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458037?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:30","pubTimestamp":1788953401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA9H1DXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665357033","title":"Palvella Therapeutics Director Makes Eye-Catching Insider Move in Latest Stock Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2665357033","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665357033?lang=en_us&edition=fundamental","pubTime":"2026-09-05 10:06","pubTimestamp":1788574019,"startTime":"0","endTime":"0","summary":"New insider activity at Palvella Therapeutics ( ($PVLA) ) has taken place on September 4, 2026. Director Christopher P. Kiritsy of Palvella Therape...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/palvella-therapeutics-director-makes-eye-catching-insider-move-in-latest-stock-transaction-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/palvella-therapeutics-director-makes-eye-catching-insider-move-in-latest-stock-transaction-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665359285","title":"Palvella Therapeutics Director Christopher P. Kiritsy Disposes of 313 Common Shares for $49,141","url":"https://stock-news.laohu8.com/highlight/detail?id=2665359285","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665359285?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:06","pubTimestamp":1788552360,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics director Christopher P. Kiritsy disposes of 313 common shares for $49,141Director Christopher P. Kiritsy cut his Palvella Therapeutics stake to 250 shares on Sep. 2, 2026.Sold 31","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL8JbKBC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Palvella Therapeutics Director Christopher P. Kiritsy Disposes of 313 Common Shares for $49,141","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664148816","title":"Palvella Therapeutics CEO to Speak at Cantor Global Healthcare Conference 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2664148816","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664148816?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:30","pubTimestamp":1788348651,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics CEO to speak at Cantor Global Healthcare Conference 2026Palvella Therapeutics CEO Wes Kaupinen will join a fireside chat at the Cantor Global Healthcare Conference on Sept. 9, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDLb3RZXc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","SG9999014039.USD","PVLA","LU2210150020.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4139","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3C00.GBP","LU0314104364.USD","SG9999014013.SGD","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","BK4585","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664554819","title":"Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664554819","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664554819?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:30","pubTimestamp":1788348600,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commerciali","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355020/0/en/palvella-therapeutics-to-participate-in-upcoming-healthcare-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","LABU","LU0128526141.USD","XBI","BK4139","BK4585","BK4588","HCSG","BK4137","BK4581","XLV","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881570","title":"Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881570?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:30","pubTimestamp":1788222626,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA), Protagonist Therapeuti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LU0029874061.USD","PTGX","LU0128526141.USD","BK4139","BK4137","XBI","XLV","HCSG","PVLA","BK4588","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663207065","title":"Palvella Completes Rolling FDA NDA Submission for Qtorin Rapamycin in Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2663207065","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663207065?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:31","pubTimestamp":1788175892,"startTime":"0","endTime":"0","summary":"Palvella completes rolling FDA NDA submission for QTORIN rapamycin in microcystic lymphatic malformationsPalvella Therapeutics completed a rolling NDA submission to the FDA for QTORIN 3.9% rapamycin g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL81tTRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","IE00BQXX3D17.EUR","BK4585","BK4588","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4139","SG9999014021.USD","PVLA","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BQXX3C00.GBP","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663607037","title":"Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2663607037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663607037?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:30","pubTimestamp":1788175800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUABMGH4Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070325","title":"Palvella Therapeutics - Accelerating U.S. Launch Readiness for Potential Qtorin Rapamycin Launch in H1 2027 if Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663070325?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:30","pubTimestamp":1788175800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUABMGH4Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661740234","title":"Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41","url":"https://stock-news.laohu8.com/highlight/detail?id=2661740234","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661740234?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:06","pubTimestamp":1787256381,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics COO Kathleen Goin reports sale of 4,302 common shares worth $654,184.41Palvella Therapeutics COO Kathleen Goin exercised stock options on Aug. 19, 2026, acquiring 4,302 common sh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL4yvj0V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521017","title":"Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521017?lang=en_us&edition=fundamental","pubTime":"2026-08-06 02:00","pubTimestamp":1785952826,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palvella Therapeutics (PVLA) and Lifecore Biomedical...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-lifecore-biomedical-lfcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-lifecore-biomedical-lfcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4139","LFCR","PVLA","BK4212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657654223","title":"Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657654223","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657654223?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:30","pubTimestamp":1785929400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Aug.  05, 2026  (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commerciali","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339219/0/en/Palvella-Therapeutics-to-Participate-in-the-Canaccord-Genuity-46th-Annual-Growth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657959638","title":"Palvella Therapeutics Charts Clear Path From Data To Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2657959638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657959638?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:59","pubTimestamp":1785891560,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, Inc. (($PVLA)) has held its Q2 earnings call. Read on for the main highlights of the call. Palvella Therapeutics’ latest ear...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-charts-clear-path-from-data-to-launch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-charts-clear-path-from-data-to-launch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FEBU","JOYT","BK4139","DECU","VOTE","RGLO","PMDE","VGFPF","PVLA","GXDW"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":114,"code":"91000000","status":"200"}]}}